Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
SCPH 
Scpharmaceuticals Inc (SCPH)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
06/30/2025: SCPH (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
6 Analysts rated it
Moderately tracked stock, growing coverage, gaining market and investor attention.
1 Year Target Price $15.6
1 Year Target Price $15.6
| 4 | Strong Buy |
| 2 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -17.88% | Avg. Invested days 25 | Today’s Advisory WEAK BUY |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 06/30/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 204.30M USD | Price to earnings Ratio - | 1Y Target Price 15.6 |
Price to earnings Ratio - | 1Y Target Price 15.6 | ||
Volume (30-day avg) 6 | Beta 0.36 | 52 Weeks Range 1.94 - 5.65 | Updated Date 06/30/2025 |
52 Weeks Range 1.94 - 5.65 | Updated Date 06/30/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.89 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -216.24% | Operating Margin (TTM) -151.1% |
Management Effectiveness
Return on Assets (TTM) -49.2% | Return on Equity (TTM) -934.02% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 199117954 | Price to Sales(TTM) 4.87 |
Enterprise Value 199117954 | Price to Sales(TTM) 4.87 | ||
Enterprise Value to Revenue 4.74 | Enterprise Value to EBITDA -6.69 | Shares Outstanding 52792000 | Shares Floating 31628202 |
Shares Outstanding 52792000 | Shares Floating 31628202 | ||
Percent Insiders 6.08 | Percent Institutions 76.64 |
Analyst Ratings
Rating 3 | Target Price 15.6 | Buy 2 | Strong Buy 4 |
Buy 2 | Strong Buy 4 | ||
Hold - | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Scpharmaceuticals Inc
Company Overview
History and Background
Founded in 2002, scPharmaceuticals Inc. is a biopharmaceutical company focused on developing and commercializing products that have the potential to transform the treatment of serious diseases that often require hospitalization. The company has transitioned from early-stage development to commercialization with its lead product Furoscix.
Core Business Areas
- Commercialization of Furoscix: scPharmaceuticals' primary business is the commercialization of Furoscix (furosemide injection) for subcutaneous administration. Furoscix is indicated for the treatment of congestion due to fluid overload in adult patients with New York Heart Association (NYHA) Class II and III heart failure. This avoids hospital visits and allows for outpatient self-administration.
Leadership and Structure
The leadership team includes John H. (Jack) Talley as President and Chief Executive Officer. The company has a typical biopharmaceutical structure with departments focusing on R&D, Commercial, Medical Affairs, Manufacturing and Operations, and Finance.
Top Products and Market Share
Key Offerings
- Furoscix (furosemide injection): Furoscix is the company's only commercial product to date, used to treat congestion due to fluid overload in adult patients with heart failure. Market share is currently being established post-commercial launch. Competing diuretics include intravenous furosemide and other loop diuretics administered in a hospital setting. The number of users and revenue is actively building after the first launch in 2023. Market share data is not fully established as of late 2024.
Market Dynamics
Industry Overview
The pharmaceutical industry is constantly evolving, driven by innovation, regulatory changes, and market demand. The heart failure therapeutics market is substantial and growing, with a significant need for improved outpatient treatment options.
Positioning
scPharmaceuticals is positioned as a disruptor in the heart failure treatment paradigm, aiming to reduce hospitalizations and improve patient quality of life through subcutaneous drug delivery. Its competitive advantage lies in offering a convenient, at-home alternative to traditional intravenous diuretics.
Total Addressable Market (TAM)
The estimated Total Addressable Market is several billion USD annually within the heart failure treatment space. scPharmaceuticals is positioned to capture a portion of this TAM by reducing hospital readmissions and providing a more convenient treatment option.
Upturn SWOT Analysis
Strengths
- Novel subcutaneous drug delivery system
- Potential to reduce hospital readmissions
- Convenient outpatient treatment option
- Experienced management team
Weaknesses
- Reliance on a single product (Furoscix)
- Need to establish strong market share and payer coverage
- Commercial execution risk
Opportunities
- Expanding Furoscix indications (e.g., other causes of edema)
- Developing new products using the subcutaneous delivery platform
- Partnerships with hospitals and healthcare providers
Threats
- Competition from existing diuretics and new heart failure therapies
- Reimbursement challenges from payers
- Regulatory risks
- Product liability risk
Competitors and Market Share
Key Competitors
- LLY
- AMGN
- MRK
- PFE
Competitive Landscape
scPharmaceuticals is a small player compared to established pharmaceutical giants. Its competitive advantage lies in its novel drug delivery system, offering a differentiated product for a specific patient population.
Growth Trajectory and Initiatives
Historical Growth: Historical growth primarily driven by R&D investments prior to commercialization. Currently focused on aggressive revenue growth via commercial ramp up.
Future Projections: Analysts project substantial revenue growth over the next few years as Furoscix adoption increases. Profitability is expected to be achieved in the mid-term as operating leverage is gained.
Recent Initiatives: Focus on Furoscix commercial launch, expanding market access, and building awareness among healthcare professionals.
Summary
scPharmaceuticals is a small biopharmaceutical company with a novel subcutaneous drug delivery system, primarily commercializing Furoscix. While the company has faced operating losses, it shows potential for growth through increased market access and healthcare professional acceptance. The company needs to carefully manage its cash and revenue to secure its long term financial health. Competition from established pharmaceutical companies with wider product portfolios is a significant challenge.
Peer Comparison
Sources and Disclaimers
Data Sources:
- SEC Filings
- Company Website
- Analyst Reports
Disclaimers:
The information provided is for informational purposes only and does not constitute financial advice. Investing in scPharmaceuticals carries significant risks. Market share and financial data are estimates and may vary. Consult with a qualified financial advisor before making any investment decisions.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Scpharmaceuticals Inc
Exchange NASDAQ | Headquaters Burlington, MA, United States | ||
IPO Launch date 2017-11-17 | President, CEO, Principal Executive Officer & Director Mr. John H. Tucker | ||
Sector Healthcare | Industry Biotechnology | Full time employees 162 | |
Full time employees 162 | |||
scPharmaceuticals Inc., a pharmaceutical company, focuses on developing and commercializing products to optimize the delivery of infused therapies and patient care. The company's lead product candidate is FUROSCIX that consists of formulation of furosemide, which is delivered through an on-body infusor for the treatment of congestion due to fluid overload in adults with chronic heart failure and kidney disease, as well as consists of subcutaneous loop diuretic that delivers IV equivalent diuresis at home; and FUROSCIX On-Body Infusor, a drug-device combination product consisting of FUROSCIX. Its product pipeline also includes SCP-111 (furosemide injection), an investigational pH neutral aqueous furosemide formulation that is being developed for subcutaneous administration outside of the hospital setting, including patient self-administration in the home; and SCP-111 Autoinjector, an investigational single-entity and drug-device combination product candidate consisting of a prefilled syringe containing SCP-111 preloaded into a mechanical autoinjector. The company was incorporated in 2013 and is headquartered in Burlington, Massachusetts.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.